Compare D Wave Quantum Inc (QBTS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs Repligen Corporation Common Stock — how do they compare? D Wave Quantum Inc trades at $11.56 (market cap $4.57B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 2.5× D Wave Quantum Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold D Wave Quantum Inc for 33 Days and Repligen Corporation Common Stock for 0 Days on average.
| QBTS | RGEN | |
|---|---|---|
Market Cap | $4.57B | $11.31B |
Volume | 23,941,483 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $44.78 | $194.57 |
52-Week Low | $12.03 | $102.87 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $4.07B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D-Wave Quantum (QBTS) trades at $13.38, down 2.62% with bearish technical signals despite unanimous analyst buy ratings. The company shows significant financial challenges with a P/S ratio of 347.19 and negative profitability metrics, though it maintains a 64.19% gross margin. Recent news highlights ongoing fraud investigations alongside positive business developments in quantum computing technology.
While analyst consensus projects 157% upside to $34.38 price target, substantial risks include negative cash flows, high valuation multiples, and legal uncertainties. The stock presents high-risk/high-reward potential for investors comfortable with quantum computing volatility and current financial headwinds.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
